369 related articles for article (PubMed ID: 25304790)
1. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
2. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
3. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
[TBL] [Abstract][Full Text] [Related]
4. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
[TBL] [Abstract][Full Text] [Related]
6. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.
Yoshida S; Koga F; Kobayashi S; Ishii C; Tanaka H; Tanaka H; Komai Y; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e21-7. PubMed ID: 22414281
[TBL] [Abstract][Full Text] [Related]
7. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer.
Koga F; Yoshida S; Tatokoro M; Kawakami S; Fujii Y; Kumagai J; Neckers L; Kihara K
PLoS One; 2011; 6(11):e27616. PubMed ID: 22102915
[TBL] [Abstract][Full Text] [Related]
8. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
9. Re: Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated with Chemoradiation-Based Selective Bladder-Sparing Approach.
Chang SS
J Urol; 2015 Sep; 194(3):665-6. PubMed ID: 26292854
[No Abstract] [Full Text] [Related]
10. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
11. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
[TBL] [Abstract][Full Text] [Related]
12. [OUTCOME OF BLADDER PRESERVATION USING LOW DOSE CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY INVASIVE BLADDER CANCER].
Matsushita M; Kitakaze H; Okada K; Minato N; Mori N; Yoshioka T
Nihon Hinyokika Gakkai Zasshi; 2018; 109(2):59-67. PubMed ID: 31006743
[TBL] [Abstract][Full Text] [Related]
13. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
Coen JJ; Paly JJ; Niemierko A; Kaufman DS; Heney NM; Spiegel DY; Efstathiou JA; Zietman AL; Shipley WU
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):311-6. PubMed ID: 23474117
[TBL] [Abstract][Full Text] [Related]
14. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
[TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
[TBL] [Abstract][Full Text] [Related]
17. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy.
Iwai A; Koga F; Fujii Y; Masuda H; Saito K; Numao N; Sakura M; Kawakami S; Kihara K
Jpn J Clin Oncol; 2011 Dec; 41(12):1373-9. PubMed ID: 21994208
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
[TBL] [Abstract][Full Text] [Related]
19. Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Haque W; Verma V; Aghazadeh M; Darcourt J; Butler EB; Teh BS
Clin Genitourin Cancer; 2019 Oct; 17(5):e1069-e1079. PubMed ID: 31331865
[TBL] [Abstract][Full Text] [Related]
20. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.
Keck B; Wach S; Taubert H; Zeiler S; Ott OJ; Kunath F; Hartmann A; Bertz S; Weiss C; Hönscheid P; Schellenburg S; Rödel C; Baretton GB; Sauer R; Fietkau R; Wullich B; Krause FS; Datta K; Muders MH
Int J Cancer; 2015 Jan; 136(2):443-51. PubMed ID: 24862180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
